Identification of stress degradation products of iloperidone using liquid chromatography coupled with an Orbitrap mass spectrometer.

RATIONALE Iloperidone (ILOP) is an atypical antipsychotic drug used for the treatment of schizophrenia and related psychotic disorders. Comprehensive stress testing of the ILOP drug was carried out as per ICH guidelines to understand its degradation profile. The presence of degradation products in a drug affects not only the quality, but also the safety and efficacy of drug formulation. Thus, it is essential to develop an efficient analytical method which can be useful for the separation, identification and characterization of all possible degradation products of ILOP. METHODS ILOP was subjected to various stress conditions such as acidic, basic, neutral hydrolysis, oxidation, photolysis and thermal conditions; and the resulting degradation products were investigated using LC-PDA-HRMS and MS/MS. An efficient and simple ultra-high-performance liquid chromatography (UHPLC) method has been developed on Acquity UPLC® BEH C18 column (2.1 × 100mm, 1.7 μm) using a gradient elution of heptafluorobutyric acid (0.1% HFBA) and acetonitrile as mobile phase. RESULTS ILOP was found to degrade under acidic and basic hydrolysis and oxidative stress conditions, whereas it was stable under neutral hydrolysis, thermal and photolytic conditions. A total of seven degradation products (DP1 to DP7) were identified and characterized by LC/MS/MS in positive ion mode with accurate mass measurements. The hydrolytic degradation under acidic and basic conditions produced two DPs (DP1 and DP2) and four DPs (DP4 to DP7), respectively, whereas DP3 was formed under oxidative conditions. In silico toxicity predictions showed higher probability values for DP4, DP6 and DP7, which indicates these DPs have the potential to mutate DNA. CONCLUSIONS ILOP was found to be labile under hydrolytic and oxidative conditions. The structures of the degradation products were rationalized by appropriate mechanisms. The proposed method can be effectively used for the determination and detection of ILOP and its degradation products.

[1]  F. Fernandez‐Llimos,et al.  Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy , 2016, Core evidence.

[2]  P. Garg,et al.  Characterization of stress degradation products of mirabegron using UPLC-QTOF-MS/MS and in silico toxicity predictions of its degradation products , 2015 .

[3]  A. Sangamwar,et al.  Characterization of degradation products of ivabradine by LC-HR-MS/MS: a typical case of exhibition of different degradation behaviour in HCl and H2SO4 acid hydrolysis. , 2015, Journal of mass spectrometry : JMS.

[4]  Shashikant B. Landge,et al.  Development and Validation of RP-UPLC Method for the Determination of Iloperidone, Its Related Compounds and Degradation Products in Bulk and Dosage Form , 2014 .

[5]  R. Srinivas,et al.  LC–ESI–MS/MS study of carvedilol and its stress degradation products , 2013 .

[6]  Roshan M. Borkar,et al.  Liquid chromatography/electrospray ionization tandem mass spectrometric study of milnacipran and its stressed degradation products. , 2013, Rapid communications in mass spectrometry : RCM.

[7]  P. Patel,et al.  Identification and characterization of stressed degradation products of metoprolol using LC/Q-TOF-ESI-MS/MS and MS(n) experiments. , 2012, Biomedical chromatography : BMC.

[8]  G. Reynolds Receptor mechanisms of antipsychotic drug action in bipolar disorder – focus on asenapine , 2011, Therapeutic advances in psychopharmacology.

[9]  Y. Venkateswarlu,et al.  Identification and characterization of stressed degradation products of prulifloxacin using LC-ESI-MS/Q-TOF, MSn experiments: development of a validated specific stability-indicating LC-MS method. , 2011, Journal of pharmaceutical and biomedical analysis.

[10]  S. Prabhakar,et al.  Mass spectral analysis of N-oxides of Chemical Weapons Convention related aminoethanols under electrospray ionization conditions. , 2011, Rapid communications in mass spectrometry : RCM.

[11]  G. D. Dal Pan,et al.  Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008 , 2010, Pharmacoepidemiology and drug safety.

[12]  Karen M. Alsante,et al.  A critical assessment of the ICH guideline on photostability testing of new drug substances and products (Q1B): Recommendation for revision. , 2010, Journal of pharmaceutical sciences.

[13]  C. Punt,et al.  Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death , 2009 .

[14]  A. Wheeler,et al.  Trends in Antipsychotic Prescribing in Schizophrenia in Auckland , 2006, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

[15]  W. Ray,et al.  Trends in prescribing of antipsychotic medications for US children. , 2006, Ambulatory pediatrics : the official journal of the Ambulatory Pediatric Association.

[16]  V. Bhatara,et al.  Antipsychotic prescribing trends among youths, 1997-2002. , 2005, Psychiatric services.

[17]  B. Bradbury,et al.  Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. , 2003, British journal of clinical pharmacology.

[18]  W A Ray,et al.  Antipsychotics and the risk of sudden cardiac death. , 2001, Archives of general psychiatry.

[19]  M. Cornfeldt,et al.  The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. , 1995, The Journal of pharmacology and experimental therapeutics.